literature

HIV mutation literature information.

Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naive patients in Slovenia, 2000-2004.

PMID: 16417938 2006 Virus research

Abstract: Namely, three out of 77 patients had mutations associated with resistance to NRTIs: one patient carried M184V in association with A62V, while a revertant mutation T215D was found in two patients.

In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

PMID: 16436719 2006 Antimicrobial agents and chemotherapy

Abstract: Insertions at amino acid position 69 and Q151M mutations (with or without M184V) reduced SPD754 susceptibility 5.2-fold and 14- to 16-fold, respectively (these changes gave values comparable to or less than the corresponding values for zidovudine, lamivudine, abacavir, and didanosine).

Abstract: SPD754 susceptibility was reduced 1.2- to 2.2-fold against isolates resistant to zidovudine (M41L, T215Y/F, plus a median of three additional nucleoside analogue mutations [NAMs]) and/or lamivudine (M184V) and was reduced 1.3- to 2.8-fold against isolates resistant to abacavir (L74V, Y115F, and M184V plus one other NAM) or stavudine (V75T/M,

An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.

PMID: 16513416 2006 Journal of clinical virology

Abstract: RESULTS: Changes at three codons (M41L, L210W, T215Y/F/D/C/E) were associated with a worse VR and three mutations (K70R, M184V, K219Q) with a better VR.

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).

PMID: 16549962 2006 AIDS (London, England)

Abstract: METHODS: This 48-week, open-label pilot study randomly assigned HIV-infected patients receiving lamivudine-containing HAART and harbouring the M184V mutation to monotherapy with lamivudine 300 mg once daily (lamivudine group) or the discontinuation of all antiretroviral drugs (TI group).

Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.

PMID: 16555278 2006 Journal of medical virology

Abstract: Among genotypic correlates, the presence of M184V and NAMs seems to be protective for the emergence of K65R, while a strong positive correlation was found with the Q151M complex mutation.

Abstract: Conversely, long 3TC exposure, and the presence of M184V or NAMs seem to be protective.

Effects of drug resistance on viral load in patients failing antiretroviral therapy.

PMID: 16555280 2006 Journal of medical virology

Abstract: Certain reverse transcriptase mutations such as M184V/I, K70R, V108I, and protease mutations such as L33FIV, M84V, and M36I were associated with reduced viral load.

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

PMID: 16640104 2006 Antiviral therapy

Abstract: Conversely, M184V showed a protective effect.

Abstract: Presence of M184V mutation was related with a greater reduction in HIV RNA during d4T/TDF exposure.

Analysis of HIV-1 replication block due to substitutions at F61 residue of reverse transcriptase reveals additional defects involving the RNase H function.

PMID: 16723431 2006 Nucleic acids research

Discussion: Although M184V mutant sequences were largely similar to those of wild type, the M184T mutant sequences included those with the insertion of tRNA in the 2-LTR junctions.

Discussion: analyzed the 2-LTR circles from M184V and M184T mutant viruses.

In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.

PMID: 16759055 2006 Antiviral therapy

Abstract: The anti-HIV activity of the combination was studied in the human T leukaemic MT-2 cell line against wild-type or mutant virus (K65R and M184V) and in PBMCs against wild-type virus.

A dual superinfection and recombination within HIV-1 subtype B 12 years after primoinfection.

PMID: 16763489 2006 Journal of acquired immune deficiency syndromes (1999)

Abstract: This result suggests a superinfection with 2 HIV-1 strains, one of which showed the T215Y + M184V resistance mutations.

Browser Board

Co-occurred Entities

Filtrator